>>Description of the research protocol "CA2004004"

Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)
Phase III study| Status : Ongoing (but closed to recruitment)

Additional details

Indication (or studied pathology) : Hémato-onco
Brugmann identifier : CA2004004
EudraCT identifier : 2010-020347-12
ClinicalTrials.gov identifier : NCT01239797


Involved department : Hemato-oncology
Principal investigator : Efira
Sponsor : BMS
Contact : Clinical Research Unit

>This protocol was approved by the UZ Gent ethics committee.